Zoetis (ZTS) Non-Current Debt (2013 - 2026)
Zoetis (ZTS) posted quarterly Non-Current Debt of $9.0 billion for Q1 2026, up 73.04% year-over-year from $5.2 billion in Q1 2025, and little changed quarter-over-quarter from $9.0 billion in Q4 2025.
Zoetis (ZTS) Non-Current Debt (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Non-Current Debt for 14 consecutive years, with $9.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 73.04% year-over-year to $9.0 billion; the TTM figure through Mar 2026 stood at $9.0 billion (up 73.04% YoY), while the FY2025 annual figure was $9.0 billion, up 73.22% from the prior year.
- Non-Current Debt held at $9.0 billion in Q1 2026 per ZTS's latest filing, from $9.0 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $9.0 billion in Q1 2026 and bottomed at $5.2 billion in Q3 2022.
- Historically, Non-Current Debt has averaged $6.4 billion across 5 years, with a median of $6.6 billion in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Debt dropped 20.96% — and 2025, when it surged 73.22%.
- Zoetis' Non-Current Debt stood at $6.6 billion in 2022, then rose by 0.18% to $6.6 billion in 2023, then retreated by 20.48% to $5.2 billion in 2024, then soared by 73.22% to $9.0 billion in 2025, then climbed by 0.03% to $9.0 billion in 2026.
- Business Quant data shows ZTS's Non-Current Debt at $9.0 billion in Q1 2026, $9.0 billion in Q4 2025, and $7.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 130.00 Mn |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn | 1.48 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.05 Bn |
| Mar 31, 2026 | 9.05 Bn |
| Dec 31, 2025 | 9.04 Bn |
| Sep 30, 2025 | 7.07 Bn |
| Jun 30, 2025 | 5.23 Bn |
| Mar 31, 2025 | 5.23 Bn |
| Dec 31, 2024 | 5.22 Bn |
| Sep 30, 2024 | 6.57 Bn |
| Jun 30, 2024 | 6.56 Bn |
| Mar 31, 2024 | 6.56 Bn |
| Dec 31, 2023 | 6.56 Bn |
| Sep 30, 2023 | 6.55 Bn |
| Jun 30, 2023 | 6.56 Bn |
| Mar 31, 2023 | 6.56 Bn |
| Dec 31, 2022 | 6.55 Bn |
| Sep 30, 2022 | 5.21 Bn |
| Jun 30, 2022 | 5.22 Bn |
| Mar 31, 2022 | 5.23 Bn |
| Dec 31, 2021 | 6.59 Bn |
| Sep 30, 2021 | 6.59 Bn |